1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Health & Life Co., Ltd.

Health & Life Co., Ltd.

TTPEX:1781
9.72
TWD
-0.13
(-1.32%)
-1.07EPS
559.41MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
28.91
13.05
14.44
13.33
11.27
13.03
8.88
16.33
17.13
16.82
12.68
14.9
8.4
8.48
Basic EPS, GAAP
0.59
-1.11
-1.31
-1.59
-1.44
-0.81
-1.61
4.34
-1.31
-0.37
-0.7
0.51
-1.3
-1.07
Free Cash Flow per Basic Share
2.21
-3.16
0.44
-1.49
0.17
-1.87
-1.1
-1.44
-3.06
-1.96
1.62
0.64
-0.11
-0.54
Dividend per Share
0.1
0.5
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
14.41
13.06
11.63
9.69
8.29
7.4
5.61
9.3
7.98
7.86
7.07
8.29
6.76
6.4
Tangible Book Value per Share
14.32
13.03
11.62
9.65
8.23
7.38
5.61
9.3
7.95
7.7
6.98
8.25
6.74
6.38
Basic Weighted Avg Shares
47
47
47
47
47
47
47
47
47
47
47
47
47
47
Sales/Revenue/Turnover
1,345
619
685
632
534
618
421
774
812
798
601
706
398
400
Operating Margin (%)
1.24
-14.47
-12.76
-12.38
-12.32
-9.24
-18.45
-2.16
-11.93
-5.65
-6.65
0.35
-15.93
-18.76
Depreciation Expense
25
23
21
20
18
18
16
12
17
24
24
23
15
14
Net Income, GAAP
27
-53
-62
-75
-68
-38
-76
206
-62
-18
-33
24
-62
-51
Effective Tax Rate (%)
45.75
- -
- -
- -
- -
- -
- -
22.13
- -
- -
- -
15.77
- -
- -
Profit Margin (%)
2.03
-8.53
-9.06
-11.94
-12.73
-6.23
-18.15
26.61
-7.68
-2.2
-5.53
3.43
-15.49
-12.66
Working Capital
437
372
295
208
151
116
44
338
230
198
149
359
287
266
LT Debt
- -
- -
- -
- -
- -
- -
49
61
48
48
24
198
193
194
Total Equity
683
619
551
459
393
351
266
441
378
373
335
393
321
303
Return on Invested Capital (%)
1.36
- -
- -
- -
- -
- -
- -
-2.54
- -
- -
- -
0.4
- -
- -
Return on Capital (%)
4.27
- -
- -
- -
- -
- -
- -
40.52
- -
- -
- -
5.13
- -
- -
Return on Common Equity (%)
4.39
-8.1
-10.6
-14.93
-15.97
-10.34
-24.8
58.28
-15.22
-4.67
-9.39
6.66
-17.28
-15.59

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4
4
4
LT Borrowings
190
191
193
LT Finance Leases
3
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
47
47
47
Market Capitalization
524
581
559

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
494
436
421
Cash, Cash Equivalents & STI
248
239
222
Accounts Receivable, Net
93
55
61
Inventories
119
118
111
Total Current Liabilities
207
155
155
Payables & Accruals
- -
- -
- -
ST Debt
4
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.72%
-5.39%
-18.44%
Free Cash Flow
-204.2%
-56.65%
-116.41%
Net Income, GAAP
-94.25%
-128.02%
-354.41%
Sales/Revenue/Turnover
-0.32%
-9.53%
-43.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
202
117
227
161
706
2025
122
69
90
117
398
2026
97
96
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.3
-0.23
0.29
0.15
0.51
2025
0.12
-0.86
-0.38
-0.18
-1.3
2026
-0.19
-0.32
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kuo Ho Yang
Full Time Employees
120
Sector
Health technology
Industry
Medical specialties
Address
No. 186, Jian 1st Road Taipei TP Taiwan 23553
IPO Date
Jan 9, 2004
Website
healthandlife.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Health & Life Co., Ltd. Health & Life Co., Ltd. manufactures and sells medical devices focused on cardiovascular disease management, in-vitro diagnostics, and respiratory care; its core products include vibrating mesh nebulizers, electronic blood pressure monitors, infrared thermometers, hearing aid devices, and blood glucose monitoring systems. Founded in 1996 and headquartered in New Taipei City, Taiwan, the company operates globally with manufacturing plants in China and Vietnam, R&D facilities in multiple locations worldwide, and an international sales and marketing network serving healthcare providers, doctors, and patients. It specializes in OEM production under various brands, emphasizing innovation-driven R&D, quality manufacturing processes, and health management solutions such as electronic stethoscopes and remote medical services platforms. The company maintains steady product development, including patented technologies for heart, lung, and intestinal sound measurement systems, while expanding its portfolio through ongoing improvements in existing devices and new feature integrations to support diverse customer needs across Asia, Europe, and other regions.